Apr. 15, 2022

Function Therapeutics, Inc. received official notice of a U.S. Department of Defense Peer Reviewed Medical Research Program Discovery Award for the project: Allosteric, small molecule ligands of PAR1 for the treatment of diabetic nephropathy. This award will help support the development of new parmodulins with improved properties, and their study in mouse models of chronic kidney disease in the lab of SAB member Dr. Berend Isermann (Leipzig University).

Function Therapeutics receives Dept. of Defense award.